Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 399

1.

Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.

Matsumoto Y, Chinen Y, Shimura Y, Nagoshi H, Sasaki N, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Taki T, Horiike S, Kuroda J, Taniwaki M.

Int J Hematol. 2019 Nov 4. doi: 10.1007/s12185-019-02766-z. [Epub ahead of print]

PMID:
31686349
2.

2-Methylthio Conversion of N6-Isopentenyladenosine in Mitochondrial tRNAs by CDK5RAP1 Promotes the Maintenance of Glioma-Initiating Cells.

Yamamoto T, Fujimura A, Wei FY, Shinojima N, Kuroda JI, Mukasa A, Tomizawa K.

iScience. 2019 Oct 8;21:42-56. doi: 10.1016/j.isci.2019.10.012. [Epub ahead of print]

3.

Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy.

Takimoto-Shimomura T, Shimura Y, Nagata K, Inaba T, Chinen Y, Tsukamoto T, Kobayashi T, Horiike S, Sotozono C, Kuroda J.

Ann Hematol. 2019 Oct 21. doi: 10.1007/s00277-019-03807-7. [Epub ahead of print] No abstract available.

PMID:
31637483
4.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

Int J Hematol. 2019 Sep 19. doi: 10.1007/s12185-019-02736-5. [Epub ahead of print]

PMID:
31538327
5.

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z. Epub 2019 Aug 20.

PMID:
31432396
6.

Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning.

Makino M, Yoshimoto R, Ono M, Itoko T, Katsuki T, Koseki A, Kudo M, Haida K, Kuroda J, Yanagiya R, Saitoh E, Hoshinaga K, Yuzawa Y, Suzuki A.

Sci Rep. 2019 Aug 14;9(1):11862. doi: 10.1038/s41598-019-48263-5.

7.

Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.

Yamaguchi J, Chinen Y, Takimoto-Shimomura T, Nagata H, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Uoshima N, Kaneko H, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Yokota I, Kuroda J; KOTOSG Investigators.

Leuk Lymphoma. 2019 Jul 18:1-8. doi: 10.1080/10428194.2019.1636982. [Epub ahead of print]

PMID:
31318305
8.

Treatment rationale and design of a phase II study of narrow-band ultraviolet B phototherapy for cutaneous steroid-refractory acute graft-vs-host disease following allogenic stem-cell transplantation.

Asai J, Yamaguchi J, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Katoh N, Kuroda J.

Medicine (Baltimore). 2019 Jul;98(28):e16372. doi: 10.1097/MD.0000000000016372.

9.

Number of positive lymph nodes and lymphatic invasion are significant prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma.

Suzuki S, Shimoda M, Shimazaki J, Maruyama T, Oshiro Y, Nishida K, Kuroda J, Miyoshi K, Koike N, Harada N.

Clin Exp Gastroenterol. 2019 Jun 6;12:255-262. doi: 10.2147/CEG.S207333. eCollection 2019.

10.

Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?

Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25554. [Epub ahead of print]

PMID:
31222819
11.

Tracing the natural and anthropogenic influence on the trace elemental chemistry of estuarine macroalgae and the implications for human consumption.

Ownsworth E, Selby D, Ottley CJ, Unsworth E, Raab A, Feldmann J, Sproson AD, Kuroda J, Faidutti C, Bücker P.

Sci Total Environ. 2019 Oct 1;685:259-272. doi: 10.1016/j.scitotenv.2019.05.263. Epub 2019 May 21.

PMID:
31176213
12.

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG).

Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24.

PMID:
31127456
13.

Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease.

Kawaji Y, Nagata H, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Kobayashi T, Uchiyama H, Urata Y, Kuroda J.

Ann Hematol. 2019 Jul;98(7):1785-1787. doi: 10.1007/s00277-019-03688-w. Epub 2019 Apr 13. No abstract available.

PMID:
31111176
14.

Early initiation of a factor Xa inhibitor can attenuate tissue repair and neurorestoration after middle cerebral artery occlusion.

Komori M, Ago T, Wakisaka Y, Nakamura K, Tachibana M, Yoshikawa Y, Shibahara T, Yamanaka K, Kuroda J, Kitazono T.

Brain Res. 2019 Sep 1;1718:201-211. doi: 10.1016/j.brainres.2019.05.020. Epub 2019 May 16.

PMID:
31103522
15.

Poor glycemic control and posterior circulation ischemic stroke.

Kuroda J, Matsuo R, Yamaguchi Y, Sato N, Kamouchi M, Hata J, Wakisaka Y, Ago T, Kitazono T; Fukuoka Stroke Registry Investigators.

Neurol Clin Pract. 2019 Apr;9(2):129-139. doi: 10.1212/CPJ.0000000000000608.

PMID:
31041127
16.

Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.

Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J.

Haematologica. 2019 Aug;104(8):e376-e379. doi: 10.3324/haematol.2019.217141. Epub 2019 Apr 11. No abstract available.

17.

Efficient recycling of nutrients in modern and past hypersaline environments.

Isaji Y, Kawahata H, Ogawa NO, Kuroda J, Yoshimura T, Jiménez-Espejo FJ, Makabe A, Shibuya T, Lugli S, Santulli A, Manzi V, Roveri M, Ohkouchi N.

Sci Rep. 2019 Mar 6;9(1):3718. doi: 10.1038/s41598-019-40174-9.

18.

A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.

Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto Y, Fujibayashi Y, Kuwahara-Ota S, Fujino T, Nishiyama D, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J.

Int J Hematol. 2019 May;109(5):593-602. doi: 10.1007/s12185-019-02617-x. Epub 2019 Mar 4.

PMID:
30830578
19.

Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants.

Iwatani S, Yoshida M, Yamana K, Kurokawa D, Kuroda J, Thwin KKM, Uemura S, Takafuji S, Nino N, Koda T, Mizobuchi M, Nishiyama M, Fujioka K, Nagase H, Morioka I, Iijima K, Nishimura N.

J Vis Exp. 2019 Jan 26;(143). doi: 10.3791/58806.

PMID:
30741254
20.

Association of Embolic Sources With Cause-Specific Functional Outcomes Among Adults With Cryptogenic Stroke.

Kiyuna F, Sato N, Matsuo R, Kamouchi M, Hata J, Wakisaka Y, Kuroda J, Ago T, Kitazono T; Fukuoka Stroke Registry Investigators.

JAMA Netw Open. 2018 Sep 7;1(5):e182953. doi: 10.1001/jamanetworkopen.2018.2953.

21.

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.

Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) investigators.

Int J Hematol. 2019 Mar;109(3):278-285. doi: 10.1007/s12185-018-02583-w. Epub 2019 Jan 9.

PMID:
30627868
22.

Nox4 Promotes Neural Stem/Precursor Cell Proliferation and Neurogenesis in the Hippocampus and Restores Memory Function Following Trimethyltin-Induced Injury.

Yoshikawa Y, Ago T, Kuroda J, Wakisaka Y, Tachibana M, Komori M, Shibahara T, Nakashima H, Nakashima K, Kitazono T.

Neuroscience. 2019 Feb 1;398:193-205. doi: 10.1016/j.neuroscience.2018.11.046. Epub 2018 Dec 5.

PMID:
30528855
23.

Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.

Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K.

Biol Blood Marrow Transplant. 2019 Mar;25(3):474-479. doi: 10.1016/j.bbmt.2018.11.003. Epub 2018 Nov 10.

PMID:
30423479
24.

Dural arteriovenous fistula associated with intratumor hemorrhage.

Takemoto Y, Kawano T, Ohmori Y, Nakagawa T, Ohta K, Kuroda JI, Yano S, Mukasa A.

J Clin Neurosci. 2019 Jan;59:352-355. doi: 10.1016/j.jocn.2018.10.008. Epub 2018 Oct 31.

PMID:
30391309
25.

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Blood Adv. 2018 Oct 23;2(20):2744-2754. doi: 10.1182/bloodadvances.2018020305.

26.

Roles of basal keratinocytes in actinotrichia formation.

Kuroda J, Iwane AH, Kondo S.

Mech Dev. 2018 Oct;153:54-63. doi: 10.1016/j.mod.2018.08.010. Epub 2018 Sep 6.

27.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

PMID:
30176173
28.

Correction to: Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.

Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2018 Oct;97(10):2013-2014. doi: 10.1007/s00277-018-3450-2.

PMID:
30046847
29.

Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry.

Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida SI, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I; Kansai Myeloma Forum Investigators.

Leuk Res Rep. 2018 Jul 4;10:7-10. doi: 10.1016/j.lrr.2018.07.001. eCollection 2018.

30.

BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Makino K, Nakamura H, Shinojima N, Kuroda JI, Yano S, Mikami Y, Mukasa A.

J Neurooncol. 2018 Oct;140(1):115-121. doi: 10.1007/s11060-018-2940-3. Epub 2018 Jul 2.

PMID:
29968039
31.

Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.

Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Shimura Y, Mizutani S, Horiike S, Taniwaki M, Kobayashi T, Kuroda J.

Invest New Drugs. 2019 Apr;37(2):210-222. doi: 10.1007/s10637-018-0623-8. Epub 2018 Jun 21.

PMID:
29931583
32.

Characterization of mannitol granules and powder: A comparative study using two flowability testers.

Takeuchi Y, Tomita T, Kuroda J, Kageyu A, Yonekura C, Hiramura Y, Tahara K, Takeuchi H.

Int J Pharm. 2018 Aug 25;547(1-2):106-113. doi: 10.1016/j.ijpharm.2018.05.061. Epub 2018 May 24.

PMID:
29803796
33.

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab.

Kuwahara-Ota S, Chinen Y, Mizuno Y, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tanba K, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Horiike S, Kuroda J.

Infect Drug Resist. 2018 May 14;11:701-705. doi: 10.2147/IDR.S163686. eCollection 2018.

34.

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.

Mori Y, Kinoshita S, Kanamori T, Kataoka H, Joh T, Iida S, Takemoto M, Kondo M, Kuroda J, Komatsu H.

Intern Med. 2018 Sep 15;57(18):2753-2757. doi: 10.2169/internalmedicine.9879-17. Epub 2018 May 18.

35.

Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.

Inoue Y, Nakamura T, Nakanishi H, Oishi M, Hongo F, Okihara K, Mizutani S, Kuroda J, Ukimura O.

Int J Urol. 2018 Jul;25(7):678-683. doi: 10.1111/iju.13597. Epub 2018 May 11.

36.

Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.

Takimoto-Shimomura T, Nagoshi H, Maegawa S, Fujibayashi Y, Tsukamoto T, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Mizutani S, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J.

Cancer Genomics Proteomics. 2018 May-Jun;15(3):213-223.

37.

Risk Prediction of Diabetic Nephropathy via Interpretable Feature Extraction from EHR Using Convolutional Autoencoder.

Katsuki T, Ono M, Koseki A, Kudo M, Haida K, Kuroda J, Makino M, Yanagiya R, Suzuki A.

Stud Health Technol Inform. 2018;247:106-110.

PMID:
29677932
38.

[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].

Kuroda J, Aoki H, Kondou N, Sumita T, Itoh K, Agawa S.

Gan To Kagaku Ryoho. 2018 Apr;45(4):688-690. Japanese.

PMID:
29650836
39.

Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.

Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R.

Ann Hematol. 2018 Aug;97(8):1445-1452. doi: 10.1007/s00277-018-3318-5. Epub 2018 Apr 2. Erratum in: Ann Hematol. 2018 Oct;97(10):2013-2014.

PMID:
29610968
40.

Detrimental Effects of Insufficient Warfarin Therapy - A Warning Against Imprudent Use of Warfarin for Atrial Fibrillation Patients.

Kuroda J.

Circ J. 2018 Apr 25;82(5):1258-1259. doi: 10.1253/circj.CJ-18-0292. Epub 2018 Mar 31. No abstract available.

41.

Insulin resistance and clinical outcomes after acute ischemic stroke.

Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, Kamouchi M; Fukuoka Stroke Registry Investigators.

Neurology. 2018 Apr 24;90(17):e1470-e1477. doi: 10.1212/WNL.0000000000005358. Epub 2018 Mar 30.

PMID:
29602916
42.

Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured intracranial aneurysm.

Shono Y, Sugimori H, Matsuo R, Fukushima Y, Wakisaka Y, Kuroda J, Ago T, Kamouchi M, Kitazono T.

Int J Stroke. 2018 Oct;13(7):734-742. doi: 10.1177/1747493018765263. Epub 2018 Mar 15.

PMID:
29543141
43.

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H.

Mediterr J Hematol Infect Dis. 2018 Feb 15;10(1):e2018014. doi: 10.4084/MJHID.2018.014. eCollection 2018. Review.

44.

Epidermal regulation of bone morphogenesis through the development and regeneration of osteoblasts in the zebrafish scale.

Iwasaki M, Kuroda J, Kawakami K, Wada H.

Dev Biol. 2018 May 15;437(2):105-119. doi: 10.1016/j.ydbio.2018.03.005. Epub 2018 Mar 7.

45.

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K.

Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17.

46.

Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.

Mizuno Y, Tsukamoto T, Kawata E, Uoshima N, Uchiyama H, Yokota I, Maegawa S, Takimoto T, Tanba K, Matsumura-Kimoto Y, Kuwahara-Ota S, Fujibayashi Y, Yamamoto-Sugitani M, Chinen Y, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J.

Cancer Med. 2018 Mar;7(3):655-664. doi: 10.1002/cam4.1342. Epub 2018 Feb 23.

47.

An adult-onset case of chronic active Epstein-Barr virus infection with fulminant clinical course.

Kaneko H, Taniwaki M, Matsumoto Y, Yoshida M, Shimura K, Fujino T, Uchiyama H, Kuroda J.

J Infect Chemother. 2018 Jun;24(6):479-482. doi: 10.1016/j.jiac.2017.12.021. Epub 2018 Feb 6.

PMID:
29426773
48.

[A Case Report of Gastric Carcinoma with Lymphoid Stroma Differentially Diagnosed from Malignant Lymphoma].

Yamada K, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Morimura R, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Kuroda J, Kishimoto M, Konishi E, Otsuji E.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1299-1301. Japanese.

PMID:
29394613
49.

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators.

Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29.

PMID:
29380179
50.

Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma.

Tanba K, Chinen Y, Uchiyama H, Uoshima N, Shimura K, Fuchida S, Kiyota M, Nakao M, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Kuroda J.

Blood Cancer J. 2018 Jan 25;8(1):1. doi: 10.1038/s41408-017-0043-6. No abstract available.

Supplemental Content

Loading ...
Support Center